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OBJECTIVE: Preoperative localization of pancreatic neuroen-
docrine tumors with traditional imaging fails in 40–60% of
patients. Endoscopic ultrasound (EUS) is highly sensitive in
the detection of these tumors. Previous reports included
relatively few patients or required the collaboration of mul-
tiple centers. We report the results of EUS evaluation of 82
patients with pancreatic neuroendocrine tumors.
METHODS: We prospectively used EUS early in the diag-
nostic evaluation of patients with biochemical or clinical
evidence of neuroendocrine tumors. Patients had surgical
confirmation of tumor localization or clinical follow-up of
.1 yr.
RESULTS: Eighty-two patients underwent 91 examinations
(cases). Thirty patients had multiple endocrine neoplasia
syndrome type I. One hundred pancreatic tumors were vi-
sualized by EUS in 54 different patients. The remaining 28
patients had no pancreatic tumor or an extrapancreatic tu-
mor. Surgical/pathological confirmation was obtained in 75
patients. The mean tumor diameter was 1.51 cm and 71% of
the tumors were#2.0 cm in diameter. Of the 54 explora-
tions with surgical confirmation of a pancreatic tumor, EUS
correctly localized the tumor in 50 patients (93%). Twenty-
nine insulinomas, 18 gastrinomas, as well as one glu-
cagonoma, one carcinoid tumor, and one somatostatinoma
were localized. The most common site for tumor localiza-
tion was the pancreatic head (46 patients). Most tumors
were hypoechoic, homogenous, and had distinct margins.
EUS of the pancreas was correctly negative in 20 of 21
patients (specificity, 95%). EUS was more accurate than
angiography with or without stimulation testing (secretin for
gastrinoma, calcium for insulinoma), transcutaneous ultra-
sound, and CT in those patients undergoing further imaging
procedures. EUS was not reliable in localizing extrapancre-
atic tumors.
CONCLUSIONS: In this series, the largest single center expe-
rience reported to date, EUS had an overall sensitivity and
accuracy of 93% for pancreatic neuroendocrine tumors. Our
results support the use of EUS as a primary diagnostic
modality in the evaluation and management of patients with
neuroendocrine tumors of the pancreas. (Am J Gastroenterol
2000;95:2271–2277. © 2000 by Am. Coll. of Gastroenter-
ology)
INTRODUCTION
Although neuroendocrine tumors of the pancreas develop in
relatively few patients, their small size and protean clinical
manifestations both fascinate and frustrate clinicians. They
occur with a prevalence of approximately 10 per 1 million
persons, usually presenting in the fourth or fifth decade of
life. The tumors cause distinct clinical syndromes associated
with an elevated hormone level, in the case of functioning
tumors, or with tumor mass effects in the case of nonfunc-
tioning tumors (1). Endocrine tumors of the pancreas may
produce a variety of hormones including insulin, gastrin,
pancreatic polypeptide, vasoactive intestinal peptide, and
somatostatin. The most common clinical syndrome is
caused by insulinomas, which are located in the pancreas in
.90% of patients (1), followed by gastrinomas, which are
extrapancreatic in location in up to 44% of patients (2).
Approximately one-half of neuroendocrine tumors are
malignant, a designation based on the presence of metasta-
ses as well as vascular or lymphatic invasion rather than
tumor histology. Even in the case of malignant disease, the
prognosis for patients with neuroendocrine tumors is far
better than their counterparts with pancreatic adenocarci-
noma and a significant number of patients can expect cure
with surgical resection (3, 4). This feature, coupled with the
fact that many of the tumors are very small, typically,2
cm, make preoperative localization both critical and highly
challenging (5).
Preoperative localization studies using extracorporeal ul-
trasound, CT, and angiography fail to localize the primary
tumor in 40–60% of patient, and frequently miss small
tumors (,2 cm) (5, 6). Recently, arterial stimulation of the
tumor with the appropriate secretagogue followed by selec-
tive portal venous sampling, has improved localization sen-
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sitivity and specificity. Doppman and colleagues (7) re-
ported a sensitivity of 88% for insulinoma localization using
intra-arterial calcium stimulation, a result that surpassed
abdominal ultrasound, CT, MRI), arteriography, and portal
venous sampling, which had sensitivities of 9%, 17%, 43%,
36%, and 67%, respectively. Analogous studies by the same
group using secretin injection for gastrinoma detection dem-
onstrated reduced sensitivity (41%) but high specificity
(98%) and was believed to have assisted the clinical man-
agement of 22% of patients (8).
Recent studies using somatostatin receptor scintigraphy
have noted impressively high detection rates for neuroen-
docrine tumors (9–13). However, it is often not possible to
differentiate uptake in pancreatic glandular tissueversusan
adjacent lymph node, nor does the test localize the tumor to
a specific anatomical region of the pancreas (11, 12). An-
other limitation of the study results is that up to 20% of
insulinomas do not express somatostatin receptors, making
the use of this imaging modality not useful in those patients
(11, 12, 14, 15).
The use of endoscopic ultrasound (EUS) in the diagnosis
and localization of pancreatic neuroendocrine tumors has
become increasingly routine. It is relatively noninvasive
with low morbidity and essentially no mortality. In a mul-
ticenter retrospective study, Rosch and colleagues (16) re-
ported a sensitivity of 82% (32 of 39 patients) using radial
scanning endoscopic ultrasound to localize pancreatic neu-
roendocrine tumors, a result that was significantly more
sensitive than angiography (sensitivity, 27%). Although
some centers have reported sensitivities of nearly 100%
with the use of intraoperative ultrasound in combination
with palpation by the surgeon, many surgeons find this
technique cumbersome and associated with prolonged op-
erating room time (17, 18, 20, 21).
Rapidly after the introduction of EUS at our center, the
procedure has been prospectively used in all patients with
suspected pancreatic neuroendocrine tumor early in the pre-
operative evaluation strategy (22). This report evaluates our
results using EUS in the diagnosis, localization, and man-




We prospectively performed 91 examinations in 82 patients
during the period from March 1993 to April 1998 who were
referred to our institution with biochemical, radiological, or
clinical evidence of neuroendocrine tumors. EUS was used
as the initial imaging technique per our previously published
management algorithm (22). Thirty-nine men and 43
women with an average age of 46.3 yr (range, 16–79 yr)
were included. Forty-six examinations were done for sus-
pected gastrinoma; of these, 30 were in patients with known
or suspected multiple endocrine neoplasia type I (MEN I)
syndrome. Thirty-eight studies were performed for sus-
pected insulinoma, two for nonfunctioning islet cell tumors,
two for carcinoid tumors, one each for suspected soma-
tostatinoma, glucagonoma, and nesidioblastosis. Confirma-
tion of the final diagnosis was obtained, usually by surgical
pathology, in 75 of 91 patients. Results from additional
imaging studies, such as transabdominal ultrasound, CT,
angiography, selective arterial secretin infusion (for gastri-
nomas), intra-arterial calcium stimulation (for insulinomas),
somatostatin receptor scintigraphy, and portal venous sam-
pling studies, in most cases performed within our institution
after EUS, were reviewed. The endosonographer was not
blinded to the results of previous imaging studies, which
typically failed to identify a lesion.
Endoscopic Ultrasound Imaging
Patients with insulinoma underwent EUS as the initial, and
often the only, preoperative imaging study, whereas patients
with gastrinoma underwent CT scanning to detect metastatic
disease, as previously described (22). EUS was performed
with either the Olympus UM-20 (Olympus America, Inc.,
Lake Success, NY) or the Pentax FG 32 UA (Pentax Pre-
cision Instruments Corp., Orangeburg, NY) echoendo-
scopes. Eighty-five of the 91 examinations were believed to
be complete. Of the five incomplete examinations, three
were attributable to lack of or poor visualization of the tail
region of the pancreas, one because of poor visualization of
the uncinate process, and one examination was limited by
the fact that the tumor discovered was too large to be
adequately imaged. A single experienced endosonographer
(JMS) performed.95% of the examinations. There was no
difference in the accuracy of tumor localization with either
instrument. Twelve examinations were performed using the
Pentax linear array echoendoscope and 79 were performed
using the Olympus radial array echoendoscope. Before the
EUS examination, a routine upper endoscopy was per-
formed in patients with gastrinoma to rule out submucosal
tumors of the upper GI tract.
The echoendoscope was advanced to the descending du-
odenum beyond the major ampulla and slowly withdrawn
from the duodenum to the stomach. To ensure that all
regions of the gland were visualized, regional anatomy of
the pancreas was verified by its relationship to the surround-
ing vessels and organs. The tumor’s size, echotexture, lo-
cation within the pancreas, involvement of the peripancre-
atic vessels, and the presence of regional lymph nodes were
documented and compared to surgical findings. All exami-
nations required approximately 30 to 60 min to complete.
Conscious sedation was achieved with intravenous meper-
idine and diazepam.
If EUS results were negative and clinical suspicion war-
ranted further investigation, patients underwent selective
angiography with venous sampling to localize the tumor.
The accuracy of tumor localization was based on operative
description and pathological confirmation of the tumor.
Clinical outcome was determined by review of postopera-
tive visits in the medical record. Cure was defined as nor-
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malization of biochemical abnormalities and resolution of
the relevant clinical syndrome. Statistical analysis used the
x2 test with Yates’ correction.
RESULTS
Endoscopic Ultrasound Imaging
Eighty-two patients underwent a total of 91 examinations
(cases) by EUS. Nine patients underwent two EUS exami-
nations because of recurrent clinical or biochemical abnor-
malities. One hundred tumors were visualized in 54 differ-
ent patients, in 38 patients no tumor was found in the
pancreas by EUS. The mean diameter of all tumors seen by
EUS was 1.51 cm. The smallest lesion measured 0.4 cm and
the largest 4.8 cm; seventy-one tumors (71%) were 2.0 cm
or less in diameter.
The performance characteristics of EUS were defined by
the results of 75 patients with definitive confirmation of
tumor status. On the basis of the results of surgery, EUS
correctly localized the pancreatic tumor in 50 of 54 patients
(93%) in which tumors were present. Eighteen of 18 gas-
trinomas (Fig. 1), 29 of 33 insulinomas (Fig. 2), as well as
one glucagonoma, one carcinoid tumor, and one soma-
tostatinoma were localized by EUS. In a patient with MEN
I syndrome, EUS identified two pancreatic tumors produc-
ing pancreatic polypeptide and vasoactive intestinal peptide.
Table 1 reports the performance characteristics of EUS
based on clinical syndrome. The specificity of EUS for
pancreatic gastrinomas is quite high (94%), as is its accu-
Figure 1. EUS appearance of a pancreatic neck 1.5 by 2.4-cm
gastrinoma, imaged at a frequency of 7.5 MHz with the Olympus
UM-20 echoendoscope positioned in the stomach.
Figure 2. (A) EUS image of a 1.0 by 1.1-cm insulinoma in the pancreatic body seen with the Olympus UM-20 echoendoscope at a
frequency setting of 7.5 MHz.(B) EUS appearance of the tumor in(A) imaged with the Olympus UM-20 echoendoscope at 12 MHz. The
higher frequency and image magnification allows recognition of the subtle isoechoic nature of the tumor.
Table 1. Localization of Pancreatic Neuroendocrine Tumors:










Sensitivity 93% 100% 88%
Specificity 95% 94% 100%
PPV 98% 95% 100%
NPV 83% 100% 43%
Accuracy 93% 97% 89%
PPV 5 positive predictive value; NPV5 negative predictive value.
* Includes one each: glucagonoma, somatostatinoma, and carcinoid tumor.
† Includes three patients with negative EUS: two with probable MEN I and
nesidioblastosis, the third with repeat testing inconsistent with insulinoma.
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racy (97%). Furthermore, a negative EUS quite reliably
predicted an extrapancreatic location for the tumor. Con-
versely, in patients with suspected insulinomas, a negative
EUS examination is less reliable in excluding pancreatic
disease (negative predictive value, 43%) and is a function of
the nearly uniform pancreatic location for these tumors.
The most common location for the visualized tumors was
the pancreatic head region (46) followed by the body (24)
(Table 2). Overall, most tumors were hypoechoic, homog-
enous, and had distinct margins (Table 3). One tumor, an
insulinoma, was hyperechoic with irregular margins. Only
one ampullary neuroendocrine tumor was visualized. This
tumor stained positive for somatostatin on immunohisto-
chemistry and was hypoechoic, homogenous with smooth
borders. The only glucagonoma detected had similar EUS
features.
Three patients with multiple masses detected on EUS had
additional tumors found on surgical excision. These were all
in patients with multiple endocrine neoplasia and all addi-
tional tumors were very small (,2 mm). Despite this, EUS
accurately directed surgical excision and all three patients
are doing well$12 months after the procedure.
Among the 36 patients with gastrinoma, diagnostic en-
doscopy identified a tumor in the stomach or duodenum in
four patients (11%). Three of these patients had the MEN I
syndrome, whereas one had sporadic disease.
Endoscopic Ultrasound Imaging
Versus Alternative Imaging Modalities
Of the 14 patients who underwent angiography, a tumor, as
depicted by a blush in the respective region of the pancreas,
was seen in only four patients (44%). Endoscopic ultra-
sonography proved significantly more accurate and was
positive in 13 of these 14 patients (93%) (p , 0.05 byx2
test). Only one tumor detected by angiography was not
detected by EUS. Alternatively, EUS detected a tumor in
four patients who had negative angiographic results.
Of the eight patients who underwent selective angiogra-
phy with calcium infusion, a tumor, detected by a stepwise
increase in insulin concentration in the portal venous system
after calcium stimulation, was correctly identified in seven
of eight patients (accuracy, 88%). Three additional tumors
were detected that were not detected with EUS; however, in
two patients testing was falsely positive and in two, testing
agreed with EUS results.
Of the nine patients with suspected gastrinomas who
underwent angiography, one tumor was correctly localized
and the other eight were correctly negative giving a sensi-
tivity and specificity for both of 100%. The one tumor
visualized by angiography was also detected on EUS.
Therefore, no additional tumors were detected by angiog-
raphy, which were not localized by EUS.
Eight patients with suspected gastrinomas also underwent
selective angiography with secretin infusion (SASI). Of
these, SASI incorrectly suggested tumor presence in seven
patients and was correctly negative in one patient (specific-
ity, 12%). No additional tumors were detected using SASI
that were not seen on EUS. In one patient, selective angiog-
raphy with secretin infusion was performed after negative
EUS and negative angiography and appeared to be positive.
Both EUS and angiography were repeated and were again
negative. A second SASI was then negative and no pancre-
atic tumor was found on subsequent surgical exploration.
Endoscopic ultrasonography of the pancreas was cor-
rectly negative in 20 of 21 patients (specificity, 95%). The
single patient considered to have a false-positive EUS had
MEN I syndrome with an elevated serum gastrin. No addi-
tional studies, for example, selective angiography with se-
cretin infusion, were performed before surgery. On explo-
ration, the lesions visualized on EUS were found to be cysts
and no pancreatic mass was detected.
Patient Outcome
Follow-up data ranging from 9 to 60 months was available
in .90% of patients. Of the patients with suspected MEN I
syndrome,.90% with a positive EUS underwent surgery,
typically a distal pancreatectomy with enucleation of prox-
imal gland tumors, which resulted in cure as determined by
resolution of the clinical syndrome and normalization of
laboratory values. One patient with suspected MEN I syn-
Table 2. Tumor Location in the Pancreas as Determined by EUS
Tumor Type Head/Neck Body Tail Uncinate
Gastrinoma 27 18 8 8
Insulinoma† 18 6 8 4
All* 46 24 16 13
* Combined data for all tumor types; does not include one patient with an ampullary
tumor.
† Includes multiple tumors in some patients.
Table 3. Ultrasonographic Features of the Pancreatic Endocrine
Tumors Detected by Endoscopic Ultrasound
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drome and a negative EUS was explored and a peripancre-
atic lymph node positive for gastrinoma was removed. This
node was identified on preoperative EUS. Because MEN I
syndrome patients may continue to develop new tumors,
these “cures” must be considered an outcome of uncertain
duration because of the underlying genetic defect.
Three patients with a negative EUS also had negative
surgical exploration. Of the patients who underwent EUS
for suspicion of sporadic gastrinoma and then went on to
laparotomy, cure was obtained in nearly 80% of patients.
Three patients with sporadic gastrinoma and negative EUS
had no findings on surgical exploration and have been
managed medically. All patients with suspected insulinomas
who had positive EUS findings were explored and cured.
One patient with a negative EUS was found to have an
extrapancreatic tumor at laparotomy. This was resected and
has resulted in cure.
The largest tumor imaged by EUS, a nonfunctioning islet
cell tumor, measured 4.8 by 3.9 cm and was located in the
head region of the pancreatic gland. Initially, this patient
presented with an episode of abdominal pain and a prelim-
inary CT scan revealed a large pancreatic head mass. De-
spite concern over possible superior mesenteric artery inva-
sion, a Whipple procedure was attempted because of the
patient’s young age (47 yr). On surgical exploration the
tumor was found to invade only the superior mesenteric vein
sparing the superior mesenteric artery and the portal vein. A
successful Whipple procedure with partial resection of the
involved portion of the superior mesenteric vein and pri-
mary anastomosis was performed. The patient remains well
with no clinical or radiographic recurrence of the tumor.18
months after surgery.
DISCUSSION
Currently, there is a multitude of potential imaging methods
available for the localization of neuroendocrine tumors of
the pancreas. EUS has the ability of producing high-reso-
lution images of the pancreas and surrounding structures. It
has the added advantage over conventional imaging tech-
niques, such as CT or MRI, of recognizing even small
tumors (1 cm or less) with remarkable accuracy. Arterial
stimulation with venous sampling, using either secretin or
calcium, is invasive, technically demanding, and expensive.
Previous studies evaluating the usefulness of EUS re-
ported a high level of sensitivity in the diagnosis of neu-
roendocrine tumors of the pancreas, but included relatively
few patients or required the collaboration of multiple cen-
ters. (5, 16, 18, 20, 21, 23–25) This adds the potential
confounding factors of varying operator experience and
different imaging techniques from center to center, issues
that are known to have a significant impact on image quality
and, hence, test sensitivity. This study presents our experi-
ence with the use of EUS for localizing neuroendocrine
tumors of the pancreas and currently is the largest published
single center experience worldwide.
We have previously reported, in abstract form, that EUS
had an overall sensitivity of 83% and an accuracy of 89%
for pancreatic neuroendocrine tumors and 100% accuracy in
excluding pancreatic gastrinoma. Our current analysis is
consistent with these previous observations with sensitivity
of 93% and overall accuracy of 93% for all neuroendocrine
tumor types combined. Our sensitivity for pancreatic gas-
trinomas continues to be 100%, a figure seldom duplicated
by other imaging modalities. As previously stated, a signif-
icant proportion of gastrinomas lie outside the pancreas and
it is our practice to routinely perform upper endoscopy
before EUS in patients with a suspected gastrinoma. We
identified additional tumors in 11% of patients with this
approach. A negative EUS of the pancreas invariably pre-
dicted an extrapancreatic location and helped to direct the
surgical exploration for the tumor.
Endoscopic ultrasonography detected 29 of 34 pancreatic
insulinomas giving sensitivity slightly below that of the
calcium stimulation but a much higher specificity. In this
series, the calcium stimulation test gave false-positive re-
sults in two of seven patients; these results may have mis-
guided surgery. For insulinomas, EUS performed signifi-
cantly better than conventional angiography, which had a
sensitivity of only 44%. Furthermore, we report a high
positive predictive value (100%) but a low negative predic-
tive value (43%). This can be explained in part by the
prestudy selection bias making the prevalence of insulinoma
in our study population quite high. The majority of the
false-negative EUS examinations occurred early in our ex-
perience, supporting the value of previous procedural expe-
rience.
Of the four false-negative EUS findings, all occurred in
patients with insulinomas. In the first patient, the pancreatic
head was believed to be “inhomogenous” without a discreet
mass. Selective angiography with calcium infusion was
performed in this patient and was negative as well. During
the initial surgery, no discrete mass was appreciated but
head resection did show positive immunohistochemistry for
insulinoma. This patient developed postsurgical hypoglyce-
mia and on repeated exploration a Whipple procedure was
done revealing a 3-cm mass. In the second patient, EUS was
believed to be suboptimal because of retroperitoneal fat, but
did not reveal a discrete pancreatic mass. A subsequent
angiography with calcium infusion was positive; however, a
repeat EUS was suboptimal and again did not show a
pancreatic lesion. On surgical exploration, the patient was
found to have a pedunculated insulinoma arising from the
head region of the pancreas. In the case of the most recent
false-negative EUS, both selective arterial angiography and
angiography with calcium infusion were positive. At sur-
gery, the patient was found to have a 1.2-cm tumor within
the uncinate process 3 cm from the wall of the duodenum.
A CT scan performed before EUS was also falsely negative.
We believe that all of our false-positive results are a func-
tion of the individual tumor characteristics or location.
Recently, somatostatin receptor scintigraphy (SRS) has
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undergone technical improvements and has gained more
widespread use in the diagnosis and management of gastro-
enteric neuroendocrine tumors. This technique uses an oc-
treotide analog labeled with indium 111 (Octreoscan 111)
administered intravenously (19). The radionucleotide iden-
tifies neuroendocrine tumors by binding to somatostatin
receptors expressed by the tumors. SRS is capable of ex-
amining the entire body at one time, thereby detecting
possible metastatic foci. The fact that up to 20% of neu-
roendocrine tumors, particularly insulinomas, do not ex-
press somatostatin receptors somewhat limits its applicabil-
ity (26). This is most pronounced for insulinomas where up
to 40% of tumors will not express somatostatin receptors
and cannot be visualized by SRS (14, 15). Another limita-
tion of scintigraphy is an inability to distinguish disease
presence in a peripancreatic lymph nodeversusin the pan-
creatic gland itself. These problems can be reduced, but not
eliminated by the use of single-photon emission CT.
In a study of gastrinomas, Gibrilet al. (9) compared SRS
to CT, MRI, and transabdominal ultrasound and reported an
overall sensitivity for SRS of 70% and 92% sensitivity for
detecting hepatic metastases. The sensitivity for SRS was
greater than all other imaging modalities combined but it
still missed 20% of gastrinomas. This study did not evaluate
the usefulness of EUS. In another study, the ability of SRS
to detect duodenal wall and peripancreatic lymph node
gastrinomas was compared to other imaging modalities in-
cluding EUS (27). The investigators report low but identical
sensitivities of 58% for both EUS and SRS and illustrate the
difficulty of localizing duodenal gastrinomas. Combining
these two modalities resulted in a sensitivity of 90% (17 of
19 patients) for tumor localization. Endoscopic ultrasound
detected all tumors visualized by any other conventional
technique (excluding SRS) calling into question the real
usefulness of these other imaging procedures.
In a recent study by Lebhatiet al. (12), somatostatin
receptor scintigraphy for the detection of gastroenteropan-
creatic tumors was compared to other imaging techniques
including EUS. One-half of the study population of 160
patients had Zollinger-Ellison syndrome, 38 had a carcinoid
tumor, and 44 patients had other types of neuroendocrine
tumors. Patients with insulinomas were not included. Only
21 patients in the group without known metastases under-
went surgery, limiting an accurate comparison between SRS
and EUS. Overall, conventional imaging including EUS was
positive in 71% of 160 patients compared to 78% with
positive SRS. Results of EUS alone were not reported.
These researchers note a clear influence of tumor size on
detection rates and report a sensitivity of only 38% for
resected tumors that were,10 mm in size. This factor has
a much less pronounced effect on EUS detection rates.
In summary, report of the largest single-center experience
to date demonstrates the impressive success of EUS in
accurately localizing pancreatic neuroendocrine tumors and
directing their surgical management. Our analysis reveals a
high sensitivity and specificity for EUS in the detection of
pancreatic neuroendocrine tumors. Currently, endoscopic
ultrasonography plays a primary and central role at our
enter in localizing these tumors preoperatively (18). The
accuracy of EUS is in part related to endosonographer
experience and undoubtedly contributes to our center’s suc-
cess with this technique. Extensive experience with pancre-
atic EUS ($100 cases/yr) is likely a key ingredient to the
success seen in this study. We believe that frequent com-
munication between the surgeon and the endosonographer is
essential to develop expertise in evaluating these lesions.
Further prospective studies comparing EUS to other imag-
ing modalities, such as somatostatin receptor scinitigraphy
and positron emission tomography scanning are needed. A
prospective study comparing EUS with SRS is currently
ongoing at our institution. Currently, approaches to preop-
erative localization of these tumors should be dictated by
local preference and expertise, and ideally should include
EUS if available.
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